Durward C M, Hartman T J, Nickols-Richardson S M
Department of Nutritional Sciences, The Pennsylvania State University, 110 Chandlee Building, University Park, PA 16801, USA.
J Obes. 2012;2012:460321. doi: 10.1155/2012/460321. Epub 2012 Dec 5.
Mortality risk across metabolic health-by-BMI categories in NHANES-III was examined. Metabolic health was defined as: (1) homeostasis model assessment-insulin resistance (HOMA-IR) <2.5; (2) ≤2 Adult Treatment Panel (ATP) III metabolic syndrome criteria; (3) combined definition using ≤1 of the following: HOMA-IR ≥1.95 (or diabetes medications), triglycerides ≥1.7 mmol/L, HDL-C <1.04 mmol/L (males) or <1.30 mmol/L (females), LDL-C ≥2.6 mmol/L, and total cholesterol ≥5.2 mmol/L (or cholesterol-lowering medications). Hazard ratios (HR) for all-cause mortality were estimated with Cox regression models. Nonpregnant women and men were included (n = 4373, mean ± SD, age 37.1 ± 10.9 years, BMI 27.3 ± 5.8 kg/m², 49.4% female). Only 40 of 1160 obese individuals were identified as MHO by all definitions. MHO groups had superior levels of clinical risk factors compared to unhealthy individuals but inferior levels compared to healthy lean groups. There was increased risk of all-cause mortality in metabolically unhealthy obese participants regardless of definition (HOMA-IR HR 2.07 (CI 1.3-3.4), P < 0.01; ATP-III HR 1.98 (CI 1.4-2.9), P < 0.001; combined definition HR 2.19 (CI 1.3-3.8), P < 0.01). MHO participants were not significantly different from healthy lean individuals by any definition. While MHO individuals are not at significantly increased risk of all-cause mortality, their clinical risk profile is worse than that of metabolically healthy lean individuals.
研究了美国国家健康与营养检查调查(NHANES)-III中按BMI类别划分的代谢健康状况下的死亡风险。代谢健康定义为:(1)稳态模型评估-胰岛素抵抗(HOMA-IR)<2.5;(2)≤2条成人治疗小组(ATP)III代谢综合征标准;(3)使用以下≤1条的综合定义:HOMA-IR≥1.95(或糖尿病药物)、甘油三酯≥1.7 mmol/L、高密度脂蛋白胆固醇(HDL-C)<1.04 mmol/L(男性)或<1.30 mmol/L(女性)、低密度脂蛋白胆固醇(LDL-C)≥2.6 mmol/L以及总胆固醇≥5.2 mmol/L(或降胆固醇药物)。使用Cox回归模型估计全因死亡率的风险比(HR)。纳入非孕妇和男性(n = 4373,均值±标准差,年龄37.1±10.9岁,BMI 27.3±5.8 kg/m²,49.4%为女性)。在1160名肥胖个体中,只有40名被所有定义确定为代谢健康肥胖(MHO)。与不健康个体相比,MHO组的临床风险因素水平更高,但与健康瘦体重组相比则更低。无论采用何种定义,代谢不健康的肥胖参与者的全因死亡风险均增加(HOMA-IR HR 2.07(CI 1.3 - 3.4),P < 0.01;ATP-III HR 1.98(CI 1.4 - 2.9),P < 0.001;综合定义HR 2.19(CI 1.3 - 3.8),P < 0.01)。无论采用何种定义,MHO参与者与健康瘦体重个体均无显著差异。虽然MHO个体的全因死亡风险没有显著增加,但其临床风险状况比代谢健康的瘦体重个体更差。